AGRX - Agile Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development14,42820,92925,622
Selling General and Administrative12,3838,7927,467
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-26,811-29,721-33,089
Income from Continuing Operations
Total Other Income/Expenses Net425351-1,141
Earnings Before Interest and Taxes-26,386-29,370-34,230
Interest Expense1,9182,4462,077
Income Before Tax-28,304-31,816-36,307
Income Tax Expense--3,075-5,972
Minority Interest---
Net Income From Continuing Ops-28,304-28,741-31,371
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-28,304-28,741-30,335
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-28,304-28,741-30,335